Sugi Predict

Sugi Predict / Compounds / SCHEMBL3410205

SCHEMBL3410205

SCHEMBL3410205

CC1OB(c2cnn(C3CCN(C(=O)OC(C)(C)C)CC3)c2)OC1(C)C

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DDB1 Q16531 1/20 0.48
▸ CRBN Q96SW2 1/20 0.48
▸ USP30 Q70CQ3 1/20 0.41
▸ CCNC P24863 1/20 0.41
▸ CDK8 P49336 1/20 0.41
▸ MET P08581 1/20 0.40
▸ JAK2 O60674 1/20 0.39
▸ JAK3 P52333 1/20 0.39
▸ PTK2 Q05397 1/20 0.39
▸ IRAK4 Q9NWZ3 1/20 0.39
▸ GPR119 Q8TDV5 6/20 0.38
▸ FGFR1 P11362 1/20 0.38
▸ FGFR2 P21802 1/20 0.38
▸ FGFR4 P22455 1/20 0.38
▸ FGFR3 P22607 1/20 0.38
▸ KDR P35968 1/20 0.38
▸ FLT3 P36888 1/20 0.38
▸ TNK2 Q07912 1/20 0.38
▸ RECQL P46063 1/20 0.37
▸ TTK P33981 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30984683 0.89 DDB1 (0.38) DDB1CRBNUSP30CCNCCDK8
SCHEMBL320828 0.87 USP30 (0.52) DDB1CRBNUSP30CCNCCDK8
SCHEMBL11961184 0.86 MAP3K7 (0.40) JAK3
SCHEMBL25238268 0.83 USP30 (0.49) DDB1CRBNUSP30CCNCCDK8
SCHEMBL21473877 0.83 DDB1 (0.49) DDB1CRBNUSP30CCNCCDK8
SCHEMBL12720747 0.82 DDB1 (0.47) DDB1CRBNUSP30CCNCCDK8
SCHEMBL2423601 0.81 USP30 (0.55) DDB1CRBNUSP30CCNCCDK8
SCHEMBL2422527 0.81 USP30 (0.55) DDB1CRBNUSP30CCNCCDK8
SCHEMBL2422530 0.81 USP30 (0.55) DDB1CRBNUSP30CCNCCDK8
SCHEMBL23901264 0.81 DDB1 (0.47) DDB1CRBNUSP30CCNCCDK8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11407732-B1 Tricyclic degraders of Ikaros and Aiolos C4 THERAPEUTICS, INC. (US) 2022-08-09 — — US disclosed
WO-2020210630-A1 TRICYCLIC DEGRADERS OF IKAROS AND AIOLOS C4 THERAPEUTICS, INC. (US) 2020-10-15 — — WO disclosed
US-8822468-B2 3-Methyl-imidazo[1,2-b]pyridazine derivatives NOVARTIS AG (CH) 2014-09-02 — — US disclosed
EP-2265614-A1 IMIDAZO [1,2-B]PYRIDAZINE DERIVATIVES FOR THE TREATMENT OF C-MET TYROSINE KINASE MEDIATED DISEASE Novartis AG (CH) 2010-12-29 — — EP disclosed
US-20090264406-A1 3-METHYL-IMIDAZO[1,2-B]PYRIDAZINE DERIVATIVES NOVARTIS AG 2009-10-22 — — US disclosed
WO-2009106577-A1 IMIDAZO [1,2-B] PYRIDAZINE DERIVATIVES FOR THE TREATMENT OF C-MET TYROSINE KINASE MEDIATED DISEASE NOVARTIS AG (CH) 2009-09-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264406-A1 3-METHYL-IMIDAZO[1,2-B]PYRIDAZINE DERIVATIVES MET, ERBB2, ALK DDB1 3415/4885CRBN 115/4885USP30 3460/4885
US-11407732-B1 Tricyclic degraders of Ikaros and Aiolos CRBN, IKZF1, IKZF3 DDB1 352/4885CRBN 1/4885USP30 132/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.